News
Topline data announced from Phase II BLAZE 4 study of bamlanivimab, VIR 7831 (GSK 4182136) which reduced viral load by 70% in COVID 19 patients. Eli Lilly/GSK/Vir Biotech
Eli Lilly and Company , Vir Biotechnology, Inc. and GlaxoSmithKline plc , announced topline data from the expanded Phase II BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 percent (p<0.001) relative reduction in persistently high viral load (> 5.27; cycle threshold value < 27.5) at day 7 compared to placebo, meeting the primary endpoint.
In addition, bamlanivimab administered with VIR-7831 demonstrated a statistically significant reduction compared to placebo in the key virologic secondary endpoints of mean change from baseline to days 3, 5 and 7 in SARS-CoV-2 viral load. There were no events for the secondary endpoint of COVID-19 related hospitalization or death by day 29 in either study arm. One patient (in the treatment arm) visited the emergency room for COVID-19 related symptoms. No serious adverse events were seen with co-administration of bamlanivimab and VIR-7831.
0.001)>
Condition: Coronavirus/COVID-19 Infection
Type: drug